Velocity Bio
About Velocity Bio
Develops high-throughput biochemical assays to identify small-molecule drugs that target under-drugged human enzymes. This approach addresses the challenge of discovering therapeutic candidates for enzymes with limited existing drug options, accelerating the drug discovery process for neglected targets.
```xml <problem> Many human enzymes are considered "under-drugged," meaning there are few or no effective small-molecule drugs available to modulate their activity. This lack of chemical tools hinders basic research and limits therapeutic options for diseases linked to these enzymes. Identifying selective inhibitors or activators for these enzymes is challenging due to the lack of validated screening methods. </problem> <solution> The company develops and applies high-throughput biochemical assays to discover small-molecule drugs that target under-drugged human enzymes. Their approach involves creating robust, sensitive assays that can screen large chemical libraries to identify compounds that selectively modulate the activity of specific enzymes. By focusing on enzymes with limited existing drug options, the company aims to accelerate the drug discovery process and expand the therapeutic landscape for neglected targets. The assays are designed to identify both inhibitors and activators, providing a comprehensive approach to modulating enzyme function. </solution> <features> - High-throughput screening platform for identifying small-molecule modulators of enzyme activity - Biochemical assays optimized for under-drugged human enzymes - Capability to screen large chemical libraries for selective inhibitors and activators - Development of custom assays tailored to specific enzyme targets </features> <target_audience> The primary audience includes pharmaceutical companies, biotechnology firms, and academic research institutions seeking to discover novel drug candidates for under-drugged enzyme targets. </target_audience> ```
What does Velocity Bio do?
Develops high-throughput biochemical assays to identify small-molecule drugs that target under-drugged human enzymes. This approach addresses the challenge of discovering therapeutic candidates for enzymes with limited existing drug options, accelerating the drug discovery process for neglected targets.
Where is Velocity Bio located?
Velocity Bio is based in San Francisco, United States.
When was Velocity Bio founded?
Velocity Bio was founded in 2023.
How much funding has Velocity Bio raised?
Velocity Bio has raised 3000000.
- Location
- San Francisco, United States
- Founded
- 2023
- Funding
- 3000000
- Employees
- 6 employees
- Major Investors
- Mission BioCapital